Trial 3L-23-1


A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Janet Luong, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.